Literature DB >> 20337574

The natural tumor suppressor protein maspin and potential application in non small cell lung cancer.

Fulvio Lonardo1, Xiaohua Li, Alexander Kaplun, Ayman Soubani, Seema Sethi, Shirish Gadgeel, Shijie Sheng.   

Abstract

The grim prognosis of lung cancer, that has an overall 10-15% survival at 5 years, remains in the US the leading cause of cancer mortality, provides a compelling rationale for studying the molecular basis of this malignancy. Surmising the common, general association with smoking, lung cancers differ at the microscopic, anatomical, epidemiological and clinical level and harbor complex genetic and epigenetic alterations. Currently, lung cancer is divided into small cell lung carcinoma (SCLC) and non small cell lung carcinoma (NSCLC) for the purpose of clinical management. (NSCLC) constitutes 80-85% of lung cancers and is further divided into histological subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, etc. The ultimate goal for lung cancer research is to develop a strategy to block the tumor progression and improve the prognosis of lung cancer. This goal can realistically be achieved only when the biological complexity of this disease is taken into account. To this end, identification and understanding of molecular markers that are mechanistically involved in tumor progression is needed. Our recent studies suggest histological subtype-dependent distinct correlations between the expression and/or subcellular localization of tumor suppressive maspin with the progression and prognosis of NSCLC. Maspin is an epithelial specific member of the serine protease inhibitor (serpin) superfamily but recently identified as an endogenous inhibitor of histone deacetylase 1 (HDAC1). This novel biochemical activity coincides with a consensus emerged recently from the evidence that nuclear maspin confers better differentiated epithelial phenotypes, decreased tumor angiogenesis, increased tumor sensitivity to drug-induced apoptosis, and a more favorable prognosis. In the current review, we discuss the evidence that maspin may be a marker that stratifies the progression and prognosis of different subtypes of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20337574      PMCID: PMC2908495          DOI: 10.2174/138161210791208974

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  55 in total

Review 1.  Cytogenetic and molecular aspects of lung cancer.

Authors:  Anna D Panani; Charis Roussos
Journal:  Cancer Lett       Date:  2005-08-19       Impact factor: 8.679

2.  Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.

Authors:  Fulvio Lonardo; Konstantin H Dragnev; Sarah J Freemantle; Yan Ma; Natalie Memoli; David Sekula; Elisabeth A Knauth; Jean S Beebe; Ethan Dmitrovsky
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

3.  Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.

Authors:  H Biliran; S Sheng
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

4.  High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma.

Authors:  W Xia; Y K Lau; M C Hu; L Li; D A Johnston; S j Sheng; A El-Naggar; M C Hung
Journal:  Oncogene       Date:  2000-05-11       Impact factor: 9.867

5.  Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.

Authors:  B Nisman; G Amir; J Lafair; N Heching; O Lyass; T Peretz; V Barak
Journal:  Anticancer Res       Date:  1999 Jul-Aug       Impact factor: 2.480

6.  Maspin sensitizes breast carcinoma cells to induced apoptosis.

Authors:  Ning Jiang; Yonghong Meng; Suliang Zhang; Edith Mensah-Osman; Shijie Sheng
Journal:  Oncogene       Date:  2002-06-13       Impact factor: 9.867

Review 7.  Histone acetylation modifiers in the pathogenesis of malignant disease.

Authors:  U Mahlknecht; D Hoelzer
Journal:  Mol Med       Date:  2000-08       Impact factor: 6.354

Review 8.  Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin.

Authors:  P A Wade
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

9.  The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.

Authors:  R McGowen; H Biliran; R Sager; S Sheng
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

10.  Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice.

Authors:  M Zhang; Y Shi; D Magit; P A Furth; R Sager
Journal:  Oncogene       Date:  2000-12-07       Impact factor: 9.867

View more
  12 in total

1.  An Essential Role of Maspin in Embryogenesis and Tumor Suppression.

Authors:  Sijana H Dzinic; M Margarida Bernardo; Xiaohua Li; Rodrigo Fernandez-Valdivia; Ye-Shih Ho; Qing-Sheng Mi; Sudeshna Bandyopadhyay; Fulvio Lonardo; Semir Vranic; Daniel S M Oliveira; R Daniel Bonfil; Gregory Dyson; Kang Chen; Almasa Omerovic; Xiujie Sheng; Xiang Han; Dinghong Wu; Xinling Bi; Dzenana Cabaravdic; Una Jakupovic; Marian Wahba; Aaron Pang; Deanna Harajli; Wael A Sakr; Shijie Sheng
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

2.  Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry.

Authors:  Shiwu Wu; Lan Yu; Zenong Cheng; Wenqing Song; Lei Zhou; Yisheng Tao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-06-09

3.  Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors.

Authors:  Haydee Lara; Yuhua Wang; Adriana S Beltran; Karla Juárez-Moreno; Xinni Yuan; Sumie Kato; Andrea V Leisewitz; Mauricio Cuello Fredes; Alexei F Licea; Denise C Connolly; Leaf Huang; Pilar Blancafort
Journal:  J Biol Chem       Date:  2012-07-10       Impact factor: 5.157

4.  Expression and localization of maspin in cervical cancer and its role in tumor progression and lymphangiogenesis.

Authors:  Zhiqiang Liu; Yangyang Shi; Wei Meng; Yufang Liu; Kaixuan Yang; Shuhua Wu; Zhilan Peng
Journal:  Arch Gynecol Obstet       Date:  2014-02       Impact factor: 2.344

5.  Maspin expression in prostate tumor elicits host anti-tumor immunity.

Authors:  Sijana H Dzinic; Kang Chen; Archana Thakur; Alexander Kaplun; R Daniel Bonfil; Xiaohua Li; Jason Liu; M Margarida Bernardo; Allen Saliganan; Jessica B Back; Hiroshi Yano; Dana L Schalk; Elyse N Tomaszewski; Ahmed S Beydoun; Gregory Dyson; Adelina Mujagic; David Krass; Ivory Dean; Qing-Sheng Mi; Elisabeth Heath; Wael Sakr; Lawrence G Lum; Shijie Sheng
Journal:  Oncotarget       Date:  2014-11-30

6.  Maspin expression patterns differ in the invasive versus lepidic growth pattern of pulmonary adenocarcinoma.

Authors:  Fulvio Lonardo; Hui Guan; Sijana Dzinic; Shijie Sheng
Journal:  Histopathology       Date:  2014-09-09       Impact factor: 5.087

7.  Aberrant Maspin mRNA Expression is Associated with Clinical Outcome in Patients with Pulmonary Adenocarcinoma.

Authors:  Mingjie Lu; Jun Li; Zebo Huang; Yiping Du; Shidai Jin; Jian Wang
Journal:  Med Sci Monit       Date:  2016-01-13

8.  The secretion and biological function of tumor suppressor maspin as an exosome cargo protein.

Authors:  Ivory Dean; Sijana H Dzinic; M Margarida Bernardo; Yi Zou; Vickie Kimler; Xiaohua Li; Alexander Kaplun; James Granneman; Guangzhao Mao; Shijie Sheng
Journal:  Oncotarget       Date:  2017-01-31

9.  Identification of an intrinsic determinant critical for maspin subcellular localization and function.

Authors:  Sijana H Dzinic; Alexander Kaplun; Xiaohua Li; Margarida Bernardo; Yonghong Meng; Ivory Dean; David Krass; Paul Stemmer; Namhee Shin; Fulvio Lonardo; Shijie Sheng
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

10.  Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.

Authors:  Benjamin Garcia-Bloj; Colette Moses; Agustin Sgro; Janice Plani-Lam; Mahira Arooj; Ciara Duffy; Shreyas Thiruvengadam; Anabel Sorolla; Rabab Rashwan; Ricardo L Mancera; Andrea Leisewitz; Theresa Swift-Scanlan; Alejandro H Corvalan; Pilar Blancafort
Journal:  Oncotarget       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.